Biogenerics drugs are the biological products manufactured after end of patent of innovator biopharmaceuticals. Biogenerics also known as biosimilars in Europe, follows-on-biologics in US and subsequent entry biological in Japan. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. Biogenerics drugs provide effective treatment for number of serious and life-threatening illnesses because of their high specificity and activity. Biogeneric are more complex compared to small molecule drugs. Their quality and safety are highly dependent on the process of production (choice of cell type, development of the genetically modified cell for production, etc.), purification and formulation. The constitution of the biogeneric drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biogeneric drugs are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biogenerics can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biogeneric drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.

Biogeneric drugs market is expected to increase in forecast period due to increased treatment options, value added services to care patient and healthcare community. Due to drugs introduces competition, increasing affordability of biologics which delivers saving for healthcare systems are the same factors which increase biogeneric drugs market. Introduction of affordable, high-quality biogeneric drugs improves access to life changing medicine for patients worldwide. Opportunities for generic drug products is huge but there are regulations that must be adhered to when strategizing the best ways to maximize a company’s return. Government regulation may be adhere the growth of drug development investment or planning an entry into a market with a new biogeneric products.

The global Biogeneric Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Biogeneric Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Biogeneric Drugs market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Biogeneric Drugs in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes their Biogeneric Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market. The following manufacturers are covered:

- Sandoz International
- Teva pharmaceutical industries
- Mylan
- 3SBio
- Shanghai Fosun Pharmaceutical
- Tonghua Dongbao Pharmaceutical
- Biocon
- Reliance life sciences
- Probiomed
- Biosidus
- AMEGA Biotech
- Celltrion
- LG Life Science
- Dong-A Pharmaceutical

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Insulins
Growth Hormones
Monoclonal Antibodies
Others

Segment by Application
Hospital
Clinics
Research Centers

Table of Contents
Executive Summary
1 Industry Overview of Biogeneric Drugs
1.1 Definition of Biogeneric Drugs

1.2 Biogeneric Drugs Segment by Type
   • 1.2.1 Global Biogeneric Drugs Production Growth Rate Comparison by Types (2014-2025)
   • 1.2.2 Insulins
   • 1.2.3 Growth Hormones
   • 1.2.4 Monoclonal Antibodies
   • 1.2.5 Others

1.3 Biogeneric Drugs Segment by Applications
   • 1.3.1 Global Biogeneric Drugs Consumption Comparison by Applications (2014-2025)
   • 1.3.2 Hospital
   • 1.3.3 Clinics
   • 1.3.4 Research Centers

1.4 Global Biogeneric Drugs Overall Market
   • 1.4.1 Global Biogeneric Drugs Revenue (2014-2025)
   • 1.4.2 Global Biogeneric Drugs Production (2014-2025)
   • 1.4.3 North America Biogeneric Drugs Status and Prospect (2014-2025)
   • 1.4.4 Europe Biogeneric Drugs Status and Prospect (2014-2025)
   • 1.4.5 China Biogeneric Drugs Status and Prospect (2014-2025)
   • 1.4.6 Japan Biogeneric Drugs Status and Prospect (2014-2025)
   • 1.4.7 Southeast Asia Biogeneric Drugs Status and Prospect (2014-2025)
   • 1.4.8 India Biogeneric Drugs Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
   • 2.1 Raw Material and Suppliers
   • 2.2 Manufacturing Cost Structure Analysis of Biogeneric Drugs
   • 2.3 Manufacturing Process Analysis of Biogeneric Drugs
   • 2.4 Industry Chain Structure of Biogeneric Drugs

3 Development and Manufacturing Plants Analysis of Biogeneric Drugs
   • 3.1 Capacity and Commercial Production Date
   • 3.2 Global Biogeneric Drugs Manufacturing Plants Distribution
   • 3.3 Major Manufacturers Technology Source and Market Position of Biogeneric Drugs
   • 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
   • 4.1 Biogeneric Drugs Production and Capacity Analysis
   • 4.2 Biogeneric Drugs Revenue Analysis
   • 4.3 Biogeneric Drugs Price Analysis
   • 4.4 Market Concentration Degree

5 Biogeneric Drugs Regional Market Analysis
   • 5.1 Biogeneric Drugs Production by Regions
     • 5.1.1 Global Biogeneric Drugs Production by Regions
     • 5.1.2 Global Biogeneric Drugs Revenue by Regions
   • 5.2 Biogeneric Drugs Consumption by Regions
   • 5.3 North America Biogeneric Drugs Market Analysis
     • 5.3.1 North America Biogeneric Drugs Production
     • 5.3.2 North America Biogeneric Drugs Revenue
     • 5.3.3 Key Manufacturers in North America
     • 5.3.4 North America Biogeneric Drugs Import and Export
   • 5.4 Europe Biogeneric Drugs Market Analysis
     • 5.4.1 Europe Biogeneric Drugs Production
     • 5.4.2 Europe Biogeneric Drugs Revenue
     • 5.4.3 Key Manufacturers in Europe
     • 5.4.4 Europe Biogeneric Drugs Import and Export
   • 5.5 China Biogeneric Drugs Market Analysis
     • 5.5.1 China Biogeneric Drugs Production
     • 5.5.2 China Biogeneric Drugs Revenue
     • 5.5.3 Key Manufacturers in China
     • 5.5.4 China Biogeneric Drugs Import and Export
   • 5.6 Japan Biogeneric Drugs Market Analysis
     • 5.6.1 Japan Biogeneric Drugs Production
     • 5.6.2 Japan Biogeneric Drugs Revenue
     • 5.6.3 Key Manufacturers in Japan
     • 5.6.4 Japan Biogeneric Drugs Import and Export
   • 5.7 Southeast Asia Biogeneric Drugs Market Analysis
     • 5.7.1 Southeast Asia Biogeneric Drugs Production
     • 5.7.2 Southeast Asia Biogeneric Drugs Revenue
     • 5.7.3 Key Manufacturers in Southeast Asia
     • 5.7.4 Southeast Asia Biogeneric Drugs Import and Export
   • 5.8 India Biogeneric Drugs Market Analysis
     • 5.8.1 India Biogeneric Drugs Production
     • 5.8.2 India Biogeneric Drugs Revenue
     • 5.8.3 Key Manufacturers in India
     • 5.8.4 India Biogeneric Drugs Import and Export

6 Biogeneric Drugs Segment Market Analysis (by Type)
   • 6.1 Global Biogeneric Drugs Production by Type
   • 6.2 Global Biogeneric Drugs Revenue by Type
   • 6.3 Biogeneric Drugs Price by Type

7 Biogeneric Drugs Segment Market Analysis (by Application)
   • 7.1 Global Biogeneric Drugs Consumption by Application
   • 7.2 Global Biogeneric Drugs Consumption Market Share by Application (2014-2019)

8 Biogeneric Drugs Major Manufacturers Analysis
   • 8.1 Sandoz International
9 Development Trend of Analysis of Biogeneric Drugs Market

9.1 Global Biogeneric Drugs Market Trend Analysis
9.1.1 Global Biogeneric Drugs Market Size (Volume and Value) Forecast 2019-2025
9.2 Biogeneric Drugs Regional Market Trend
9.2.1 North America Biogeneric Drugs Forecast 2019-2025
9.2.2 Europe Biogeneric Drugs Forecast 2019-2025
9.2.3 China Biogeneric Drugs Forecast 2019-2025
9.2.4 Japan Biogeneric Drugs Forecast 2019-2025
9.2.5 Southeast Asia Biogeneric Drugs Forecast 2019-2025
9.2.6 India Biogeneric Drugs Forecast 2019-2025
9.3 Biogeneric Drugs Market Trend (Product Type)
9.4 Biogeneric Drugs Market Trend (Application)
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Biogeneric Drugs Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion

13 Appendix
13.1 Methodology/Research Approach
13.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List